Bonekamp, David http://orcid.org/0000-0002-4811-0087
Wolf, M. B.
Roethke, M. C.
Pahernik, S.
Hadaschik, B. A.
Hatiboglu, G.
Kuru, T. H.
Popeneciu, I. V.
Chin, J. L.
Billia, M.
Relle, J.
Hafron, J.
Nandalur, K. R.
Staruch, R. M.
Burtnyk, M.
Hohenfellner, M.
Schlemmer, H.-P.
Article History
Received: 8 January 2018
Revised: 8 May 2018
Accepted: 1 June 2018
First Online: 25 June 2018
Compliance with ethical standards
:
: The scientific guarantor of this publication is Heinz-Peter Schlemmer.
: David Bonekamp is speaker for Profound Medical Inc.Mathieu Burtnyk is director of clinical affairs of Profound Medical Inc. with a salary and stock options.Robert Staruch is senior clinical scientist at Profound Medical Inc., with a salary and stock options.Jason M. Hafron declares: Amgen-paid speaker, Armune Biosciences Inc, advisory board/paid speaker, Dendreon-Advisory Board, paid speaker, Myriad, and paid speaker, United Physicians- Board of directorsHeinz-Peter Schlemmer declares: Consulting fee or honorarium: Siemens, Curagita, Profound, Bayer. Travel support: Siemens, Curagita, Profound, Bayer. Board Member: Curagita. Consultancy: Curagita, Bayer. Grants/Grants pending: BMBF, Deutsche Krebshilfe, Dietmar-Hopp-Stiftung, Roland-Ernst-Stiftung. Payment for lectures: Siemens, Curagita, Profound, Bayer.Boris Hadaschik declares: Personal fees: Janssen, BMS, Astrellas, Bayer. Grants: Janssen, Astrellas, BMS, German Cancer Aid, German Research Foundation.Grant: Profound Medical.Gencay Hatiboglu declares: Consultancy for BMS.Timur Kuru has nothing to declare.James Relle has nothing to declare.Maya Mueller-Wolf has nothing to declare.Matthias Röthke declares consulting fee and payment for lectures: Siemens Healthineers, Curagita AG.Sascha Pahernik reports personal fees from Bayer, personal fees from Astellas, personal fees from Janssen, outside the submitted work.Valentin Popeneciu has nothing to declare.Joseph Chin declares: Investigator and consultant for Profound Medical Inc., US HIFU, Endocare; Paid Advisory Board/Consultancy for Abbvie, Johnson & Johnson/Janssen, Amgen, Tersera, Novartis, Astellas, Bayer, Sanofi-Aventis.Michele Billia has nothing to declare.Kiran Nandalur has nothing to declare.Markus Hohenfellner has nothing to declare.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in Chin JL, Billia M, Relle J, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective Phase 1 clinical trial. Eur Urol. 2016;70(3):447–455.
: • prospective• experimental• multicentre study